CELI Questrade - DR

The chart shows the growth of an initial investment of CA$10,000 in CELI Questrade - DR, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Feb 6, 2025, CELI Questrade - DR's average daily return is +0.14%, while the average monthly return is +2.84%. At this rate, an investment would double in approximately 2.1 years.

Historically, 67% of months were positive and 33% were negative. The best month was Sep 2025 with a return of +13.6%, while the worst month was Feb 2025 at -8.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 2 months.

On a daily basis, CELI Questrade - DR closed higher 58% of trading days. The best single day was Apr 9, 2025 with a return of +11.6%, while the worst single day was Apr 3, 2025 at -5.6%.

CELI Questrade - DR has an annualized alpha of 25.79%, beta of 1.24, and R² of 0.60 versus S&P 500 Index. Calculated based on daily prices since February 06, 2025.

• This portfolio captured 317.28% of S&P 500 Index gains and 145.26% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• This portfolio generated an annualized alpha of 25.79% versus S&P 500 Index — delivering returns beyond what market exposure alone would predict.

CELI Questrade - DR has an expense ratio of 0.23%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

CELI Questrade - DR ranks 58 for risk / return — on par with similar portfolios. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

CELI Questrade - DR Sharpe ratios as of Apr 16, 2026 (values are recalculated daily):

• 1-Year: 2.98
• All Time: 1.30

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 2.19 to 3.00, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of CELI Questrade - DR compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

CELI Questrade - DR provided a 3.58% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CELI Questrade - DR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CELI Questrade - DR was 24.60%, occurring on Apr 8, 2025. Recovery took 34 trading sessions.

The current CELI Questrade - DR drawdown is 5.54%.

The chart below shows the rolling one-month volatility.